David Spigel, MD

Sarah Cannon Research Institute at Tennessee Oncology
Nashville, Tennessee, United States

Disclosure information not submitted.

Presentation(s):

• Paper 26 - A FIRST-IN-HUMAN STUDY OF CDK9 INHIBITOR KB-0742 DEMONSTRATES PRELIMINARY EVIDENCE OF CLINICAL ACTIVITY IN TRANSCRIPTIONALLY ADDICTED SARCOMAS

  Thursday, November 2, 2023
  4:00 PM – 5:30 PM